Literature DB >> 3082891

Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor.

D D Wagner, T Mayadas, V J Marder.   

Abstract

Two conditions were identified that interfered with the complex polymerization process in biosynthesis of von Willebrand factor (vWf). Treatment of human umbilical vein endothelial cells with tunicamycin inhibited N-linked glycosylation of nascent vWf and the resulting pro-vWf monomers failed to dimerize. The single subunits accumulated in the endoplasmic reticulum and were neither processed further nor secreted. In the presence of a weak base (ammonium chloride or chloroquine), interdimer disulfide bond formation was inhibited in a dose-dependent manner. This process appeared therefore to be pH sensitive and likely to be initiated in the acidic trans-Golgi apparatus (Anderson, R. G. W., and R. K. Pathak, 1985, Cell, 40: 635-643). The weak base had no obvious effect on the other processing steps, i.e. dimerization, complex carbohydrate formation and sulfation, and produced only slight inhibition of prosequence cleavage. On the other hand, the weak base interfered with the targeting of newly synthesized vWf into Weibel-Palade bodies, with all of the vWf being secreted constitutively and none stored in the Weibel-Palade bodies. In summary, initial glycosylation of the nascent vWf protein and low pH in the trans-Golgi apparatus were important conditions for the successful polymerization of human vWf. Genetic defects disrupting any one of these conditions could result in the phenotype of von Willebrand disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082891      PMCID: PMC2114173          DOI: 10.1083/jcb.102.4.1320

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  33 in total

Review 1.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

2.  Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells.

Authors:  D C Lynch; R Williams; T S Zimmerman; E P Kirby; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

Review 3.  Perturbation of vesicular traffic with the carboxylic ionophore monensin.

Authors:  A M Tartakoff
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

Review 4.  Intracellular degradation of newly synthesized secretory proteins.

Authors:  R S Bienkowski
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

5.  The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells.

Authors:  C Loesberg; M D Gonsalves; J Zandbergen; C Willems; W G van Aken; H V Stel; J A Van Mourik; P G De Groot
Journal:  Biochim Biophys Acta       Date:  1983-09-22

6.  Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain.

Authors:  D D Wagner; V J Marder
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

7.  Chloroquine diverts ACTH from a regulated to a constitutive secretory pathway in AtT-20 cells.

Authors:  H P Moore; B Gumbiner; R B Kelly
Journal:  Nature       Date:  1983 Mar 31-Apr 6       Impact factor: 49.962

8.  Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts.

Authors:  S K Basu; J L Goldstein; R G Anderson; M S Brown
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

9.  Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.

Authors:  D D Wagner; J B Olmsted; V J Marder
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

10.  Golgi membranes contain an electrogenic H+ pump in parallel to a chloride conductance.

Authors:  J Glickman; K Croen; S Kelly; Q Al-Awqati
Journal:  J Cell Biol       Date:  1983-10       Impact factor: 10.539

View more
  31 in total

Review 1.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

2.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

3.  von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.

Authors:  Sri R Madabhushi; Chengwei Shang; Kannayakanahalli M Dayananda; Kate Rittenhouse-Olson; Mary Murphy; Thomas E Ryan; Robert R Montgomery; Sriram Neelamegham
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

4.  Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor.

Authors:  Luke T Dang; Angie R Purvis; Ren-Huai Huang; Lisa A Westfield; J Evan Sadler
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

5.  Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.

Authors:  R B Levene; F M Booyse; J Chediak; T S Zimmerman; D M Livingston; D C Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

6.  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.

Authors:  Lesley G Ellies; David Ditto; Gallia G Levy; Mark Wahrenbrock; David Ginsburg; Ajit Varki; Dzung T Le; Jamey D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-03       Impact factor: 11.205

7.  Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.

Authors:  D D Wagner; P J Fay; L A Sporn; S Sinha; S O Lawrence; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Genetic linkage of two intragenic restriction fragment length polymorphisms with von Willebrand's disease type IIA. Evidence for a defect in the von Willebrand factor gene.

Authors:  C L Verweij; R Quadt; E Briët; K Dubbeldam; G B van Ommen; H Pannekoek
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

Authors:  Simon F De Meyer; Karen Vanhoorelbeke; Marinee K Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

10.  Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.

Authors:  Ren-Huai Huang; Ying Wang; Robyn Roth; Xiong Yu; Angie R Purvis; John E Heuser; Edward H Egelman; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.